Organizational Changes Further Emphasize Integration of Biology and Technology
Reese joined Amgen in 2005 as a medical improvement chief in oncology and later served as government vp of Research and Development (R&D) from 2018 to 2023. During his tenure, he led approvals of quite a few revolutionary medicines and biosimilars, superior a sturdy pipeline of potential new therapies and strengthened discovery analysis capabilities. As inaugural chief expertise officer, Reese inspired the early adoption of expertise and synthetic intelligence throughout all sides of the enterprise, specifically R&D.
“Dave recognized early the impact that advances in biology and technology would have on our industry and helped lead Amgen through that shift,” mentioned Robert A. Bradway, chairman and chief government officer at Amgen. “The capabilities he built position us to advance what we call convergent innovation and strengthen our ability to serve patients in the years ahead.”
Convergent innovation brings collectively biology, knowledge science, and superior applied sciences comparable to synthetic intelligence to speed up the invention and improvement of recent medicines and rework how sufferers, suppliers and different companions interact with the well being care system. Amgen is evolving its group to higher join these interactions with how the corporate operates. To help this, Amgen is making the next adjustments efficient June 1, 2026:
- James Bradner, M.D., will function government vp, Research and Development, Artificial Intelligence and Data. A physician-scientist with experience on the intersection of biology and expertise, Bradner has superior using rising applied sciences in biomedical analysis and brings his expertise to this subsequent part at Amgen.
- Sean Bruich will function senior vp, Chief Technology Officer. A seasoned expertise and knowledge science chief, Bruich has superior Amgen’s AI and knowledge capabilities, constructing on a profession main world insights and AI organizations via pivotal moments of trade transformation.
- Murdo Gordon will function government vp, Amgen Global Markets and Policy, which incorporates Medical, Commercial Operations, Government Affairs and Policy. Gordon brings his expertise as a frontrunner of world markets and coverage and confirmed observe document of strengthening partnerships with well being programs and clinicians to enhance entry to medicines via the adoption of superior applied sciences.
- Paul Burton, M.D., Ph.D., will proceed to function senior vp, Chief Medical Officer. A champion of medical breakthroughs and public well being, Burton stays centered on reaching clinicians and sufferers with medicines and options in areas of best unmet want, from cardiovascular to uncommon ailments.
Together, these adjustments deepen the combination of science and expertise and align the group with the evolving adoption of recent applied sciences throughout the well being care ecosystem, supporting Amgen’s skill to serve extra sufferers world wide.
About Amgen
Amgen discovers, develops, manufactures and delivers revolutionary medicines to combat among the world’s hardest ailments. Harnessing the perfect of biology and expertise, Amgen reaches thousands and thousands of sufferers with its medicines.
More than 45 years in the past, Amgen helped set up the biotechnology trade at its
Amgen has been consistently recognized for innovation and office tradition, together with honors from Fast Company and Forbes. Amgen is without doubt one of the 30 corporations that comprise the Dow Jones Industrial Average®, and additionally it is a part of the Nasdaq-100 Index®, which incorporates the biggest and most revolutionary non-financial corporations listed on the Nasdaq Stock Market based mostly on market capitalization.
For extra data, go to Amgen.com and observe Amgen on X, LinkedIn, Instagram, YouTube, Facebook, TikTok and Threads.
Amgen Forward-Looking Statements
This information launch incorporates forward-looking statements which can be based mostly on the present expectations and beliefs of Amgen. All statements, aside from statements of historic reality, are statements that might be deemed forward-looking statements, together with any statements on the end result, advantages and synergies of collaborations, or potential collaborations, with every other firm (together with BeOne Medicines Ltd.), the efficiency of Otezla® (apremilast), our acquisitions of ChemoCentryx, Inc., Dark Blue Therapeutics, Ltd. or Horizon Therapeutics plc (together with the possible efficiency and outlook of Horizon’s enterprise, efficiency and alternatives, and any potential strategic advantages, synergies or alternatives anticipated on account of such acquisition), in addition to estimates of revenues, working margins, capital expenditures, money, different monetary metrics, anticipated authorized, arbitration, political, regulatory or medical outcomes or practices, buyer and prescriber patterns or practices, reimbursement actions and outcomes, results of pandemics or different widespread well being issues on our enterprise, outcomes, progress, and different such estimates and outcomes. Forward-looking statements contain vital dangers and uncertainties, together with these mentioned under and extra totally described within the Securities and Exchange Commission experiences filed by Amgen, together with our most up-to-date annual report on Form 10-Ok and any subsequent periodic experiences on Form 10-Q and present experiences on Form 8-Ok. Unless in any other case famous, Amgen is offering this data as of the date of this information launch and doesn’t undertake any obligation to replace any forward-looking statements contained on this doc on account of new data, future occasions or in any other case.
No forward-looking assertion may be assured and precise outcomes could differ materially from these we mission. Our outcomes could also be affected by our skill to efficiently market each new and current merchandise domestically and internationally, medical and regulatory developments involving present and future merchandise, gross sales development of not too long ago launched merchandise, competitors from different merchandise together with biosimilars, difficulties or delays in manufacturing our merchandise and world financial circumstances, together with these ensuing from geopolitical relations and authorities actions. In addition, gross sales of our merchandise are affected by pricing strain, political and public scrutiny and reimbursement insurance policies imposed by third-party payers, together with governments, personal insurance policy and managed care suppliers and could also be affected by regulatory, medical and guideline developments and home and worldwide developments towards managed care and healthcare value containment. Furthermore, our analysis, testing, pricing, advertising and marketing and different operations are topic to in depth regulation by home and overseas authorities regulatory authorities. We or others may establish security, unwanted effects or manufacturing issues with our merchandise, together with our gadgets, after they’re available on the market. Our enterprise could also be impacted by authorities investigations, litigation and product legal responsibility claims. In addition, our enterprise could also be impacted by the adoption of recent tax laws or publicity to further tax liabilities. Further, whereas we routinely acquire patents for our merchandise and expertise, the safety supplied by our patents and patent functions could also be challenged, invalidated or circumvented by our opponents, or we could fail to prevail in current and future mental property litigation. We carry out a considerable quantity of our business manufacturing actions at a number of key services, together with in
CONTACT: Amgen, Thousand Oaks
Elissa Snook, 609-251-1407 (media)
Casey Capparelli, 805-447-1746 (traders)
View unique content material to obtain multimedia:https://www.prnewswire.com/news-releases/amgen-announces-retirement-of-david-m-reese-executive-vice-president-and-chief-technology-officer-302750791.html
SOURCE Amgen
